FIGURE 5.
ERK5 has an impact on survival of patients with GBM with high stem cell properties. A, mRNA expression of ERK5 in GBM tissues (n = 107) and normal tissues (n = 22) in a previous study (26). B, mRNA expression of ERK5 at each grade (grade II, n = 226; grade III, n = 241; grade IV, n = 149) in TCGA database. C, mRNA expression of ERK5 at each grade (grade II, n = 138; grade III, n = 144; grade IV, n = 140) in CGGA database. D, ssGSEA score of ERK5 signaling in GBM tissues (n = 107) and normal tissues (n = 22) in our previous data. E, ssGSEA score of ERK5 signaling at each grade (grade II, n = 226; grade III, n = 241; grade IV, n = 149) in TCGA database. F, ssGSEA score of ERK5 signaling at each grade (grade II, n = 138; grade III, n = 144; grade IV, n = 140) in CGGA database. Kaplan–Meier survival analysis of ERK5 expressionhigh (n = 67) and ERK5 expressionlow (n = 66; G), ERK5 signalinghigh (n = 38) and ERK5 signalinglow (n = 95; H), GSC signalinghigh (ERK5 expressionhigh (n = 17), ERK5 expressionlow (n = 53); ERK5 signalinghigh (n = 23), ERK5 signalinglow (n = 47; I), SOX2high [ERK5 expressionhigh (n = 27) and ERK5 expressionlow (n = 26)], c-MYChigh [ERK5 expressionhigh (n = 37) and ERK5 expressionlow (n = 36)], PROM1high [ERK5 expressionhigh (n = 34) and ERK5 expressionlow (n = 33)], FUT4high [ERK5 expressionhigh (n = 35) and ERK5 expressionlow (n = 34)], NEShigh [ERK5 expressionhigh (n = 37) and ERK5 expressionlow (n = 36; J), and SOX2high [ERK5 signalinghigh (n = 17) and ERK5 signalinglow (n = 82)], c-MYChigh [ERK5 signalinghigh (n = 33) and ERK5 signalinglow (n = 66)], PROM1high [ERK5 signalinghigh (n = 20) and ERK5 signalinglow (n = 79)], FUT4high [ERK5 signalinghigh (n = 20) and ERK5 signalinglow (n = 80)], NEShigh [ERK5 signalinghigh (n = 13) and ERK5 signalinglow (n = 86)] GBM patient groups in CGGA database (K).